Literature DB >> 4045513

Splenectomy in myasthenia gravis: a therapeutic concept?

W E Hofmann, P Reuther, B Schalke, H G Mertens.   

Abstract

The case histories are presented of five patients with long-diagnosed myasthenia gravis (up to 15 years) who underwent splenectomy. A precondition for the decision to operate was muscle weakness that could not be controlled with standard therapy (e.g. anticholinesterase drugs, immunosuppressive measures). After splenectomy, a considerable improvement took place in three cases; in one case there was moderate improvement, and in another, no improvement. The alleviation of myasthenia gravis may be attributable to the reduction of either the number of immunocompetent lymphocytes in an important storage organ or of the total bulk of the immune system in an immune disease with raised auto-antibody production. The acetylcholine receptor antibody titre was not affected by the operation in a consistent way. After splenectomy, immunosuppressive medication was tolerated better with respect to its haematological side-effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045513     DOI: 10.1007/BF00313782

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis.

Authors:  V M Monnier; B W Fulpius
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

Review 2.  Myasthenia gravis (first of two parts).

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1978-01-19       Impact factor: 91.245

3.  Overwhelming postplenectomy infection.

Authors:  W Krivit; G S Giebink; A Leonard
Journal:  Surg Clin North Am       Date:  1979-04       Impact factor: 2.741

4.  Lymphocytes as models for the study of mammalian cellular differentiation.

Authors:  H Cantor; E A Boyse
Journal:  Immunol Rev       Date:  1977-01       Impact factor: 12.988

5.  Immunological studies in children before and after splenectomy.

Authors:  V Andersen; J Cohn; S F Sorensen
Journal:  Acta Paediatr Scand       Date:  1976-07

6.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

7.  Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus-derived myogenic cells.

Authors:  H Wekerle; U P Ketelsen; A D Zurn; B W Fulpius
Journal:  Eur J Immunol       Date:  1978-08       Impact factor: 5.532

8.  Effect of immunosuppressive drugs (azathioprine).

Authors:  H G Mertens; G Hertel; P Reuther; K Ricker
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

9.  [Alterations of humoral and cellular immunity after splenectomy (author's transl)].

Authors:  M Winkelmeyer; K Littmann; O Thraenhart; G Tichy; E K Kuwert; F W Eigler
Journal:  Klin Wochenschr       Date:  1981-05-15

10.  Thymectomy in late-onset myasthenia gravis.

Authors:  C W Olanow; R J Lane; A D Roses
Journal:  Arch Neurol       Date:  1982-02
View more
  3 in total

1.  Splenectomy in the treatment of severe forms of myasthenia.

Authors:  B M Gekht; M I Kuzin; O S Shkrob; P S Vetshev; I Kh Ippolitov; A G Sanadze; D I Shagal; Z Sh Khodzhaev
Journal:  Neurosci Behav Physiol       Date:  1991 Sep-Oct

2.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

Review 3.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.